HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk



Guselkumab Sustained Long-Term Efficacy in Patients with Active Psoriatic Arthritis

March 18, 2021

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

Secukinumab Not Associated With Tuberculosis

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

Psoriasis Risk Rises with TNF Inhibitor Use in Pediatric Inflammatory Diseases

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

Methotrexate Use in Psoriasis with Arthritis Revisited

February 13, 2019

A new study in JAMA Dermatology raises an interesting question for physicians who treat psoriasis patients. Does methotrexate work best in patients with plaque psoriasis alone or patients who have both psoriasis and arthritis?